FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q42150539> ?p ?o ?g. }

• Q42150539 description "2016 nî lūn-bûn" @default.
• Q42150539 description "2016 թվականի հուլիսի 2-ին հրատարակված գիտական հոդված" @default.
• Q42150539 description "2016年の論文" @default.
• Q42150539 description "2016年論文" @default.
• Q42150539 description "2016年論文" @default.
• Q42150539 description "2016年論文" @default.
• Q42150539 description "2016年論文" @default.
• Q42150539 description "2016年論文" @default.
• Q42150539 description "2016年论文" @default.
• Q42150539 description "2016年论文" @default.
• Q42150539 description "2016年论文" @default.
• Q42150539 description "2016年论文" @default.
• Q42150539 description "2016年论文" @default.
• Q42150539 description "2016年论文" @default.
• Q42150539 description "2016년 논문" @default.
• Q42150539 description "article científic" @default.
• Q42150539 description "article scientific" @default.
• Q42150539 description "article scientifique" @default.
• Q42150539 description "articol științific" @default.
• Q42150539 description "articolo scientifico" @default.
• Q42150539 description "artigo científico" @default.
• Q42150539 description "artigo científico" @default.
• Q42150539 description "artigo científico" @default.
• Q42150539 description "artikel ilmiah" @default.
• Q42150539 description "artikull shkencor" @default.
• Q42150539 description "artikulong pang-agham" @default.
• Q42150539 description "artykuł naukowy" @default.
• Q42150539 description "artículo científico publicado en 2016" @default.
• Q42150539 description "artículu científicu espublizáu en 2016" @default.
• Q42150539 description "bilimsel makale" @default.
• Q42150539 description "bài báo khoa học" @default.
• Q42150539 description "naučni članak" @default.
• Q42150539 description "scienca artikolo" @default.
• Q42150539 description "scientific article published on 2 July 2016" @default.
• Q42150539 description "scientific article published on 2 July 2016" @default.
• Q42150539 description "scientific article published on 2 July 2016" @default.
• Q42150539 description "teaduslik artikkel" @default.
• Q42150539 description "tieteellinen artikkeli" @default.
• Q42150539 description "tudományos cikk" @default.
• Q42150539 description "vedecký článok" @default.
• Q42150539 description "vetenskaplig artikel" @default.
• Q42150539 description "videnskabelig artikel" @default.
• Q42150539 description "vitenskapelig artikkel" @default.
• Q42150539 description "vitskapeleg artikkel" @default.
• Q42150539 description "vědecký článek" @default.
• Q42150539 description "wetenschappelijk artikel" @default.
• Q42150539 description "wissenschaftlicher Artikel" @default.
• Q42150539 description "επιστημονικό άρθρο" @default.
• Q42150539 description "мақолаи илмӣ" @default.
• Q42150539 description "наукова стаття, опублікована в липні 2016" @default.
• Q42150539 description "научна статия" @default.
• Q42150539 description "научная статья" @default.
• Q42150539 description "научни чланак" @default.
• Q42150539 description "научни чланак" @default.
• Q42150539 description "מאמר מדעי" @default.
• Q42150539 description "مقالة علمية نشرت في 2 يوليو 2016" @default.
• Q42150539 description "২ জুলাই ২০১৬-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
• Q42150539 description "บทความทางวิทยาศาสตร์" @default.
• Q42150539 description "სამეცნიერო სტატია" @default.
• Q42150539 name "Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib" @default.
• Q42150539 name "Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib" @default.
• Q42150539 type Item @default.
• Q42150539 label "Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib" @default.
• Q42150539 label "Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib" @default.
• Q42150539 prefLabel "Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib" @default.
• Q42150539 prefLabel "Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib" @default.
• Q42150539 P1433 Q42150539-DC834EF1-ABD2-4E41-B8AE-6FB49C6698CA @default.
• Q42150539 P1476 Q42150539-67C3760C-B6F5-465B-927D-682F4366CE73 @default.
• Q42150539 P2093 Q42150539-8B6E7CEE-6FC4-496E-9725-DCE129916A91 @default.
• Q42150539 P2093 Q42150539-8F1BDD39-5A4E-4B9C-AC9A-AD10BCA129A9 @default.
• Q42150539 P2860 Q42150539-0E026D2A-B94B-4854-AC16-0FA6BE90BE1E @default.
• Q42150539 P2860 Q42150539-72D9695C-1211-4D33-927A-BF65F62D913B @default.
• Q42150539 P2860 Q42150539-73B20DA4-BFEE-4645-910A-08FF3F0ED904 @default.
• Q42150539 P2860 Q42150539-89B60832-2FD6-4D25-9DC7-DB4ECB2EF890 @default.
• Q42150539 P2860 Q42150539-9DB5A992-98DE-49B3-A9FA-064501FDB940 @default.
• Q42150539 P2860 Q42150539-AF9B32E9-5B0D-41D8-9A9E-B4BB019586C1 @default.
• Q42150539 P2860 Q42150539-E29B043C-5CBD-4BC5-A08D-0CC185984470 @default.
• Q42150539 P2888 Q42150539-B49E8F7A-2066-4088-8CB7-69DCC546EA05 @default.
• Q42150539 P304 Q42150539-2B4BEEA3-B571-4AE3-849D-8F81F64DE790 @default.
• Q42150539 P31 Q42150539-0FC73E96-CD9C-4923-B367-8A21CBE33112 @default.
• Q42150539 P356 Q42150539-AAF0609B-2135-4D6F-84DD-CC42252548B9 @default.
• Q42150539 P433 Q42150539-DC169C9C-A616-4AE5-BF6A-EA45B236ACAE @default.
• Q42150539 P4510 Q42150539-A4958AEA-57D4-449C-9935-82DBE60517E8 @default.
• Q42150539 P478 Q42150539-29727855-F389-45FD-8C28-DD729CB5185E @default.
• Q42150539 P50 Q42150539-BF2F5EA6-D762-402B-8DE4-DA623123C055 @default.
• Q42150539 P577 Q42150539-F51D9FB8-F621-41A5-83DD-EDB886360610 @default.
• Q42150539 P6179 Q42150539-E57D8148-6132-48E9-B793-35598D06661B @default.
• Q42150539 P698 Q42150539-B3822586-E40C-447F-90AA-F4BB627EE779 @default.
• Q42150539 P932 Q42150539-B1DBE8ED-512B-4EE3-85AA-CF65A2D1C874 @default.
• Q42150539 P356 S00280-016-3087-6 @default.
• Q42150539 P698 27372908 @default.
• Q42150539 P1433 Q326137 @default.
• Q42150539 P1476 "Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib" @default.
• Q42150539 P2093 "Edmund V Capparelli" @default.
• Q42150539 P2093 "Lisa H Lam" @default.
• Q42150539 P2860 Q27851712 @default.
• Q42150539 P2860 Q36011773 @default.
• Q42150539 P2860 Q36210439 @default.
• Q42150539 P2860 Q38253338 @default.
• Q42150539 P2860 Q45977770 @default.

• next